65,437 trials
Feeding and Eating Disorders
Primary: Subjective Rating of Fear — -36.9444; -23.9219; -47.3611; 85.6250 units on scale*minutes — p=.879
Nocturnal Enuresis · Bed Wetting
Primary: Percentage of Wet Nights — -0.104790479; -0.099141959; -0.111602158 %change wet nights
Marijuana Use · Opioid Use
Primary: Self-Administration of Drug Units Earned — 0.00; 3.83; 3.67; 0.00 Number of drug units
Post Traumatic Stress Disorder
Primary: Change From Baseline in CAPS-5 Total Severity Score — -36.2; -23.3; -13.6 points — p=0.011
Severe Aortic Stenosis · Iron-deficiency
Primary: Submaximal Exercise Test — 375; 384 meters
Pancreatic Metastatic Cancer · Toxicity
Primary: Composite Safety and Early Efficacy Assessment in the First 34 Patients — 65.8 pourcentage of participants
Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
Primary: Number of Participants With Sputum Culture Conversion in Mycobacteria Growth Indicator Tube (MGIT) at Week 24 — 3; 16 Participants — p==0.002
Cystinuria
Primary: Cystine Stone Recurrence — 16; 23 Participants
Depression, Postpartum
Primary: Proportion Sustainment of Core Program Elements — 0.34; 0.18; 0.43; 0.13 proportion of sessions — p=.12
Physical Inactivity · Type2 Diabetes Mellitus
Primary: Total Physical Activity Log Means and Geometric Means With Standard Deviation in Intervention and Control Groups After Intervention. — 216.07; 201.47 log calories/day…
Pain, Chronic
Primary: Patient Global Impression of Change (PGIC) — 66; 78; 54; 13 Participants
Dislodged Catheter · Catheter Related Complication
Primary: The Force (Newtons) Required to Dislodge an IV Catheter Secured in the Retrograde Direction. — 28.65; 15.41; 19.29 Newtons
Diabetes Mellitus · Diabetic Kidney Disease · Hypertension
Primary: To Investigate the Modifying Effect of Sodium Intake on Ertugliflozin on Blood Pressure — 125; 121; 138; 133 mmHg — p=0.0174
HIV · AIDS · Smoking Cessation
Primary: 7-day Point-prevalence Abstinence — 16; 12; 110; 114 Participants
Norovirus Infections
Primary: Number of Participants (Mothers) With Any Solicited Symptoms of Reactogenicity for 1 Week Following Trial Dose — 15; 8; 5; 1 Participants